natgillin/translations-raw huggingface dataset:
What Twynsta looks like and contents of the pack Twynsta 80 mg/10 mg tablets are blue and white oval shaped two layer tablets engraved with the product code A4 and the company logo on the white layer. 
Twynsta 80 mg/10 mg tablete su dvoslojne, plavo-bijele tablete ovalnog oblika, s utisnutom oznakom proizvoda A4 i logom tvrtke na bijelom sloju.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg telmisartan and 5 mg amlodipine (as amlodipine besilate). 
NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta sadrži 40 mg telmisartana i 5 mg amlodipina (u obliku amlodipinbesilata).
Blue and white oval shaped two layer tablets engraved with the product code A1 and the company logo on the white layer. 
Dvoslojna plavo-bijela tableta ovalnog oblika, s utisnutom oznakom proizvoda A1 i logom tvrtke na bijelom sloju.
MARKETING AUTHORISATION NUMBER(S) EU/1/10/648/007 (360 (4 x 90 x 1) tablets) 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/648/007 (360 (4 x 90 x 1) tableta)
MARKETING AUTHORISATION HOLDER 
Nositelj odobrenja za
EU/1/10/648/022 (14 tablets) EU/1/10/648/023 (28 tablets) EU/1/10/648/024 (30 x 1 tablets) EU/1/10/648/025 (56 tablets) EU/1/10/648/026 (90 x 1 tablets) EU/1/10/648/027 (98 tablets) 
EU/1/10/648/022 (14 tableta) EU/1/10/648/023 (28 tableta) EU/1/10/648/024 (30 x 1 tableta) EU/1/10/648/025 (56 tableta) EU/1/10/648/026 (90 x 1 tableta) EU/1/10/648/027 (98 tableta)
What Twynsta looks like and contents of the pack Twynsta 40 mg/10 mg tablets are blue and white oval shaped two layer tablets engraved with the product code A2 and the company logo on the white layer. 
Twynsta 40 mg/10 mg tablete su dvoslojne, plavo-bijele tablete ovalnog oblika, s utisnutom oznakom proizvoda A2 i logom tvrtke na bijelom sloju.
EU/1/10/648/008 (14 tablets) EU/1/10/648/009 (28 tablets) EU/1/10/648/010 (30 x 1 tablets) EU/1/10/648/011 (56 tablets) EU/1/10/648/012 (90 x 1 tablets) EU/1/10/648/013 (98 tablets) 
EU/1/10/648/008 (14 tableta) EU/1/10/648/009 (28 tableta) EU/1/10/648/010 (30 x 1 tableta) EU/1/10/648/011 (56 tableta) EU/1/10/648/012 (90 x 1 tableta) EU/1/10/648/013 (98 tableta)
EU/1/10/648/015 (14 tablets) EU/1/10/648/016 (28 tablets) EU/1/10/648/017 (30 x 1 tablets) EU/1/10/648/018 (56 tablets) EU/1/10/648/019 (90 x 1 tablets) EU/1/10/648/020 (98 tablets) 
EU/1/10/648/015 (14 tableta) EU/1/10/648/016 (28 tableta) EU/1/10/648/017 (30 x 1 tableta) EU/1/10/648/018 (56 tableta) EU/1/10/648/019 (90 x 1 tableta) EU/1/10/648/020 (98 tableta)
Twynsta 40 mg/10 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg alone. 
Twynsta 40 mg/10 mg tablete mogu primjenjivati bolesnici kod kojih nije postignuta odgovarajuća kontrola krvnog tlaka monoterapijom amlodipinom od 10 mg.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg telmisartan and 5 mg amlodipine (as amlodipine besilate). 
NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta sadrži 80 mg telmisartana i 5 mg amlodipina (u obliku amlodipinbesilata).
EU/1/10/648/022 (14 tablets) EU/1/10/648/023 (28 tablets) EU/1/10/648/024 (30 x 1 tablets) EU/1/10/648/025 (56 tablets) EU/1/10/648/026 (90 x 1 tablets) EU/1/10/648/027 (98 tablets) EU/1/10/648/028 (360 (4 x 90 x 1) tablets) 
EU/1/10/648/022 (14 tableta) EU/1/10/648/023 (28 tableta) EU/1/10/648/024 (30 x 1 tableta) EU/1/10/648/025 (56 tableta) EU/1/10/648/026 (90 x 1 tableta) EU/1/10/648/027 (98 tableta) EU/1/10/648/028 (360 (4 x 90 x 1) tableta)
Blue and white oval shaped two layer tablets engraved with the product code A3 and the company logo on the white layer. 
Dvoslojna plavo-bijela tableta ovalnog oblika, s utisnutom oznakom proizvoda A3 i logom tvrtke na bijelom sloju.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg telmisartan and 10 mg amlodipine (as amlodipine besilate). 
NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta sadrži 40 mg telmisartana i 10 mg amlodipina (u obliku amlodipinbesilata).
Blue and white oval shaped two layer tablets engraved with the product code A4 and the company logo on the white layer. 
Dvoslojna plavo-bijela tableta ovalnog oblika, s utisnutom oznakom proizvoda A4 i logom tvrtke na bijelom sloju.
Reduced number of white blood cells (leucopenia), low platelet count (thrombocytopenia), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), excess sugar in blood , uncontrollable twitching or jerking movements, heart attack, irregular heart beat, 
Smanjeni broj bijelih krvnih stanica (leukopenija), niski broj trombocita (tromobcitopenija), alergijska reakcija (npr. osip, svrbež, otežano disanje, piskanje pri disanju, otečenost lica ili niski krvni tlak), povećane vrijednosti šećera u krvi, nekontrolirani pokreti grčenja ili trzanja, srčani udar, nepravilno kucanje srca, upala krvnih žila, upala gušterače, upala želučane sluznice (gastritis), upala jetre, žutilo kože (žutica), povišene vrijednosti jetrenih enzima sa žuticom, brzo oticanje kože i sluznice
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg telmisartan and 10 mg amlodipine (as amlodipine besilate). 
NAVOĐENJE DJELATNE(IH) TVARI Jedna tableta sadrži 80 mg telmisartana i 10 mg amlodipina (u obliku amlodipinbesilata).
MARKETING AUTHORISATION NUMBER(S) EU/1/10/648/021 (360 (4 x 90 x 1) tablets) 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/648/021 (360 (4 x 90 x 1) tableta)
MARKETING AUTHORISATION NUMBER(S) EU/1/10/648/014 (360 (4 x 90 x 1) tablets) 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/648/014 (360 (4 x 90 x 1) tableta)
EU/1/10/648/008 (14 tablets) EU/1/10/648/009 (28 tablets) EU/1/10/648/010 (30 x 1 tablets) EU/1/10/648/011 (56 tablets) EU/1/10/648/012 (90 x 1 tablets) EU/1/10/648/013 (98 tablets) EU/1/10/648/014 (360 (4 x 90 x 1) tablets) 
EU/1/10/648/008 (14 tableta) EU/1/10/648/009 (28 tableta) EU/1/10/648/010 (30 x 1 tableta) EU/1/10/648/011 (56 tableta) EU/1/10/648/012 (90 x 1 tableta) EU/1/10/648/013 (98 tableta) EU/1/10/648/014 (360 (4 x 90 x 1) tableta)
EU/1/10/648/015 (14 tablets) EU/1/10/648/016 (28 tablets) EU/1/10/648/017 (30 x 1 tablets) EU/1/10/648/018 (56 tablets) EU/1/10/648/019 (90 x 1 tablets) EU/1/10/648/020 (98 tablets) EU/1/10/648/021 (360 (4 x 90 x 1) tablets) 
EU/1/10/648/015 (14 tableta) EU/1/10/648/016 (28 tableta) EU/1/10/648/017 (30 x 1 tableta) EU/1/10/648/018 (56 tableta) EU/1/10/648/019 (90 x 1 tableta) EU/1/10/648/020 (98 tableta) EU/1/10/648/021 (360 (4 x 90 x 1) tableta)
Uncommon visual impairment 
Tablični prikaz nuspojava
Blue and white oval shaped two layer tablets engraved with the product code A2 and the company logo on the white layer. 
Dvoslojna plavo-bijela tableta ovalnog oblika, s utisnutom oznakom proizvoda A2 i logom tvrtke na bijelom sloju.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON OF THE MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) - WITHOUT BLUE BOX - 40 mg/10 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU UNUTARNJA KUTIJA VIŠESTRUKOG PAKIRANJA OD 360 (4 PAKIRAANJA S 90 x 1 TABLETOM) - BEZ PLAVOG OKVIRA - 40 mg/10 mg
MARKETING AUTHORISATION NUMBER(S) EU/1/10/648/028 (360 (4 x 90 x 1) tablets) 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/648/028 (360 (4 x 90 x 1) tableta)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON OF THE MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) - WITHOUT BLUE BOX - 80 mg/10 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU UNUTARNJA KUTIJA VIŠESTRUKOG PAKIRANJA OD 360 (4 PAKIRANJA S 90 x 1 TABLETOM) - BEZ PLAVOG OKVIRA - 80 mg/10 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON OF THE MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) - WITHOUT BLUE BOX - 80 mg/5 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU UNUTARNJA KUTIJA VIŠESTRUKOG PAKIRANJA OD 360 (4 PAKIRANJA S 90 x 1 TABLETOM) - BEZ PLAVOG OKVIRA - 80 mg/5 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON OF THE MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) - WITHOUT BLUE BOX - 40 mg/5 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU UNUTARNJA KUTIJA VIŠESTRUKOG PAKIRANJA OD 360 (4 PAKIRANJA S 90 x 1 TABLETOM) - BEZ PLAVOG OKVIRA - 40 mg/5 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL ON MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) BUNDLEDINCLUDING THE BLUE BOX - 80 mg/10 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA NALJEPNICA NA VIŠESTRUKOM PAKIRANJU OD 360 (4 PAKIRANJA S 90 x 1 TABLETOM) - UKLJUČUJUĆI PLAVI OKVIR - 80 mg/10 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL ON MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) BUNDLEDINCLUDING THE BLUE BOX - 40 mg/10 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA NALJEPNICA NA VIŠESTRUKOM PAKIRANJU OD 360 (4 PAKIRANJA S 90 x 1 TABLETOM) - UKLJUČUJUĆI PLAVI OKVIR - 40 mg/10 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL ON MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) BUNDLEDINCLUDING THE BLUE BOX - 80 mg/5 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA NALJEPNICA NA VIŠESTRUKOM PAKIRANJU OD 360 (4 PAKIRANJA S 90 x 1 TABLETOM) - UKLJUČUJUĆI PLAVI OKVIR - 80 mg/5 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER LABEL ON MULTIPACKS OF 360 (4 PACKS OF 90 x 1 TABLETS) BUNDLEDINCLUDING THE BLUE BOX - 40 mg/5 mg 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA NALJEPNICA NA VIŠESTRUKOM PAKIRANJU OD 360 (4 PAKIRANJA S 90 x 1 TABLETOM) - UKLJUČUJUĆI PLAVI OKVIR - 40 mg/5 mg
The company also presented data from the published literature. 
Tvrtka je također dostavila podatke iz objavljene literature.
The three main studies involved a total of almost 113,000 people. 
Tri glavna ispitivanja obuhvatila su ukupno 113.000 osoba.
Once prepared, the suspension should be drunk within two hours. 
Nakon što je pripremljena, suspenziju treba popiti u roku od dva sata.
This subunit is not toxic by itself. 
Ova podjedinica nije toksična sama po sebi.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to protect itself against a disease. 
Cjepiva djeluju „učeći“ imunosni sustav (prirodnu obranu tijela) kako da se štiti protiv bolesti.
The full EPAR for Dukoral can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Dukoral nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The course should be completed at least one week before potential exposure to cholera. 
Cijeli ciklus cijepljenja treba završiti najmanje tjedan dana prije potencijalnog izlaganja koleri.
Other information about Dukoral: 
Ostale informacije o lijeku Dukoral:
Food, drink and other medicines taken by mouth should be avoided for one hour before and one hour after each dose of Dukoral. 
Hranu, pića i druge lijekove koji se uzimaju peroralno treba izbjegavati jedan sat prije i jedna sat nakon svake doze lijeka Dukoral.
Because Dukoral has been in use in Sweden since 1991, the company presented the results of three main studies that had already been carried out in order to support the use of Dukoral. 
Budući da se Dukoral primjenjuje u Švedskoj od 1991., tvrtka je dostavila rezultate tri glavna ispitivanja koja su već provedena u kako bi se potkrijepila uporaba lijeka Dukoral.
The CHMP noted that the risk of cholera for regular tourists is minor, but that Dukoral could be important for certain groups, such as healthcare workers in cholera epidemics. 
CHMP je zaključio da je rizik od kolere u prosječnih turista malen, no lijek Dukoral može biti važan za određene grupe, poput zdravstvenih radnika u slučaju epidemije kolere.
The European Commission granted a marketing authorisation valid throughout the European Union for Dukoral on 28 April 2004. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Dukoral na snazi u Europskoj uniji od 28. travnja 2004.
Dukoral should not replace standard protective measures against cholera, including advice on diet and hygiene. 
Dukoral ne smije zamijeniti standardne zaštitne mjere protiv kolere, uključujući savjet o prehrani i higijeni.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to cholera bacteria. 
U buduće, imunosni će sustav moći brže ako je izložen bakteriji kolere.
It is available as a suspension in a bottle together with effervescent granules in a sachet. 
Dostupno je kao suspenzija u boci zajedno s drugim šumećim granulama u vrećici.
Dukoral is used in adults, adolescents and children from two years of age who will be visiting high-risk areas. 
Dukoral se koristi u odraslih osoba, adolescenata i djece u dobi od dvije godine i starijih, koji planiraju posjetiti područja visokog rizika.
Dukoral should be given according to official recommendations, taking into account where cholera is found and the risk of contracting the disease. 
Dukoral treba primjenjivati u skladu sa službenim preporukama, uzimajući u obzir područja gdje je kolera prisutna i rizik od zaraze bolešću.
In adults, two vaccine doses were shown to be as effective as three. 
Utvrđeno je da su u odraslih osoba dvije doze cjepiva podjednako djelotvorne kao i tri.
Dukoral cholera vaccine (inactivated, oral) 
Dukoral cjepivo protiv kolere (inaktivirano, peroralno)
In all three studies, the main measure of effectiveness was the ‘protective effectiveness' of the vaccine, calculated by comparing the number of people in the studies who developed cholera after receiving Dukoral and after receiving placebo. 
U sva tri ispitivanja, glavna mjera djelotvornosti bila je „zaštitna djelotvornost“ cjepiva, izračunata uspoređujući broj osoba u ispitivanjima u kojih se razvila kolera nakon primanja lijeka Dukoral i nakon primanja placeba.
The people in the final study also received a booster dose 10 to 12 months later. 
Osobe u posljednjem ispitivanju također su primile booster dozu nakon 10 do 12 mjeseci.
However, the following side effects are seen in between 1 and 10 patients in 1,000: headache, diarrhoea, and abdominal (tummy) pain, cramps, gurgling (gas) or discomfort. 
No, sljedeće nuspojave mogu se javiti kod 1 do 10 bolesnika na 1.000: glavobolja, proljev i bol u abdomenu (trbuhu), grčevi, nadutost (plinovi) ili nelagoda.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Dukoral. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenilo lijek da bi donijelo svoje mišljenje u korist davanja odobrenja za stavljanje lijeka u promet i svoje preporuke o uvjetima za primjenu lijeka Dukoral.
The first study involved over 89,000 people in Bangladesh and compared Dukoral with the same vaccine without the toxin and with placebo. 
Prvo je ispitivanje obuhvatilo više od 89.000 osoba u Bangladešu, te je usporedilo Dukoral s istim cjepivom bez toksina i s placebom.
Its use should be postponed in patients with a short-lived illness affecting the stomach or gut, or with a fever. 
Primjena se treba odgoditi u bolesnika s kratkoročnom bolesti koja zahvaća želudac ili crijeva ili s groznicom.
The studies took place in areas where cholera is found. 
Ispitivanja su se održala u područjima gdje je kolera prisutna.
Dukoral is used to protect against cholera (a very serious disease caused by V. cholerae, which is caught from contaminated food or water and causes severe diarrhoea). 
Dukoral se koristi za imunizaciju protiv kolere (vrlo ozbiljne bolesti koju uzrokuje V. cholerae, od koje se obolijeva uslijed konzumacije zaražene hrane ili vode i uzrokuje teški proljev).
For more information about treatment with Dukoral, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Dukoral pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku
A further study was carried out to show that Dukoral could produce antibodies in people who do not come from areas where cholera is found. 
Provedeno je još jedno ispitivanje kako bi se dokazalo da lijek Dukoral može proizvesti protutijela u osoba koje ne potječu iz područja gdje je prisutna kolera.
The vaccine contains four different inactivated strains (types) of the bacterium Vibrio cholerae (V. cholerae) serotype O1, and part of a toxin from one of these strains as active substances. 
Cjepivo sadrži četiri različita inaktivna soja (tipa) bakterije Vibrio cholerae (V. cholerae) serotipa O1, i dio toksina iz jednog od ovih sojeva kao djelatne tvari.
The other two studies compared Dukoral (containing recombinant cholera toxin) with placebo in over 22,000 people in Peru. 
Druga dva ispitivanja usporedila su Dukoral (sadržavao je rekombinantni toksin kolere) s placebom u više od 22.000 osoba u Peruu.
Dukoral is a vaccine. 
Dukoral je cjepivo.
When a person is given the vaccine, the immune system recognises the bacteria and the toxin, and makes antibodies against them. 
Nakon što osoba primi cjepivo, imunosni sustav prepoznaje bakteriju i toksin, i proizvodi protutijela protiv njih.
Why has Dukoral been approved? 
Zašto je Dukoral odobren?
This document is a summary of the European public assessment report (EPAR) for Dukoral. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Dukoral.
The granules are dissolved in water and mixed with the vaccine before intake. 
Granule su topive u vodi i miješaju se s cjepivom prije primjene.
What is the risk associated with Dukoral? 
Koji su rizici povezani s lijekom Dukoral?
Dukoral must not be used in people who may be hypersensitive (allergic) to any of the active substances, to any of the other ingredients or to formaldehyde. 
Dukoral se ne smije primjenjivati u osoba koje su preosjetljive (alergične) na bilo koju djelatnu tvar ili na neku pomoćnu tvar ili na formaldehid.
The information presented was not sufficient to support the use of Dukoral in traveller's diarrhoea. 
Dostavljene informacije nisu bile dovoljne da potvrde uporabu lijeka Dukoral u slučaju putničkog proljeva.
The vaccine is made up by dissolving the granules in a glass of water to prepare an effervescent (sparkling) solution, and adding the contents of the bottle. 
Cjepivo se priprema otapanjem granula u čaši vode kako bi se pripremila šumeća otopina, i dodavanjem sadržaja boce.
For continuous protection against cholera, a single booster dose is recommended within two years for people from six years of age, and within six months for children aged between two and six years. 
Za potrebu kontinuirane zaštite od kolere, preporučuje se jedna booster doza unutar roka od dvije godine za osobe starije od šest godina, te unutar roka od šest mjeseci za djecu u dobi između dvije i šest godina.
Dukoral contains small amounts of inactivated (killed) cholera bacteria and a part of the cholera toxin called the ‘B subunit'. 
Dukoral sadrži male količine inaktivne (ubijene) bakterije kolere i dio toksina kolere naziva „podjedinica B“.
In all three studies, Dukoral, given as either two or three doses, was compared with placebo (a dummy vaccine). 
U sva tri ispitivanja, Dukoral, je primjenjivan u dvije ili tri doze, uspoređen je s placebom (lažnim liječenjem).
What is Dukoral? 
Što je Dukoral?
In this study, Dukoral was made using cholera toxin extracted from cholera bacteria in place of the newer recombinant toxin. 
U ovom ispitivanju, Dukoral je pripremljen pomoću toksina kolere ektrahiranog iz bakterije kolere umjesto novijeg rekombinantnog toksina.
Children aged between two and six years should receive three doses, with an interval of one to six weeks between each dose. 
Djeca u dobi između dvije i šest godina starosti trebaju primiti tri doze, u razmaku od šest tjedna između svake doze.
The length of protection was different for adults and children, lasting for six months in children and for two years in adults. 
Trajanje imunizacije razlikovalo se između odraslih osoba i djece, pri čemu je trajalo šest mjeseci u djece i dvije godine u odraslih osoba.
These antibodies will help to protect against cholera by preventing the bacteria and the toxins from attaching to the walls of the gut and entering the body's cells. 
Ova protutijela pomažu u zaštiti protiv kolere sprječavajući vezivanje bakterija i toksina za stjenke crijeva i ulaženje u tjelesne stanice.
The Committee decided that Dukoral's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je da koristi od lijeka Dukoral nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
The company also presented information on the use of Dukoral for the prevention of a severe type of traveller's diarrhoea caused by a bacterium called ‘enterotoxigenic Escherichia coli'. 
Tvrtka je dostavila informacije o prevenciji ozbiljnog tipa proljeva u putnika uzrokovanog bakterijom naziva „enterotoksigena Escherichia coli'.
The course should be repeated in adults who have not been given a booster within two years and in children not given a booster within six months. 
Ciklus cjepiva treba ponoviti u odraslih osoba koje nisu primile booster dozu unutar roka od dvije godine, te u djece koja nisu primila booster dozu unutar roka od šest mjeseci.
In the study in Bangladesh, the protective effectiveness of Dukoral was 85% over the first six months of follow-up. 
U ispitivanju provedenom u Bangladešu, zaštitna djelotvornost lijeka Dukoral bila je 85% tijekom prvih šest mjeseci kontrole.
In adults and children from six years of age, Dukoral is given as two doses, one to six weeks apart. 
U odraslih osoba i djece u dobi od šest godina i stariji, Dukoral se primjenjuje u dvije doze, jedna svakih šest tjedana.
In the first of the two studies in Peru, the protective effectiveness of Dukoral was 85% for the first five months of follow-up. 
U prvom od dva ispitivanja provedena u Peruu, zaštitna djelotvornost lijeka Dukoral iznosila je 85% tijekom prvih pet mjeseci kontrole.
Side effects with Dukoral are not common. 
Nuspojave lijeka Dukoral nisu česte.
The other study in Peru showed that after a booster dose, the protective effectiveness of Dukoral during the second year of follow-up was 61%. 
Drugim ispitivanjem provedenim u Peruu utvrđeno je da je zaštitna djelotvornost lijeka Dukoral nakon booster doze tijekom druge godine kontrole iznosila 61%.
What benefit has Dukoral shown during the studies? 
Koje su koristi lijeka Dukoral utvrđene u ispitivanjima?
What is Dukoral used for? 
Za što se Dukoral koristi?
Dukoral is a vaccine that is given by mouth. 
Dukoral je cjepivo koje se daje peroralno.
How is Dukoral used? 
Kako se Dukoral koristi?
For the full list of side effects reported with Dukoral, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Dukoral, potražite u uputi o lijeku.
How has Dukoral been studied? 
Kako je Dukoral ispitivan?
How does Dukoral work? 
Kako djeluje Dukoral?
Further information on Brinavess can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/brinavess. 
Više informacija o lijeku Brinavess dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/brinavess.
If the blood pressure or heart rate suddenly decreases the infusion should be stopped immediately. 
Ako se krvni tlak ili otkucaji srca odjednom smanje, odmah je potrebno prekinuti infuziju.
If the heart rhythm has not returned to normal 15 minutes after the end of the first infusion, a second, smaller dose may be given. 
Ako se srčani ritam nije vratio u normalu nakon 15 minuta od prve infuzije, može se dati druga, manja doza.
Patients should not be given more than 5 mg of Brinavess per kg body weight within any 24-hour period, or a maximum of 565 mg in patients weighing more than 113 kg. 
Bolesnicima se ne smije davati više od 5 mg lijeka Brinavess po kili tjelesne težine tijekom razdoblja od 24 sata, ili najviše 565 mg u bolesnika težih od 113 kg.
What is Brinavess and what is it used for? 
Što je Brinavess i za što se koristi?